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associated with long-term prognosis following
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Background: Increased levels of cardio-enriched microRNAs (miRNAs) have been described in patients with
myocardial infarction (MI). We wanted to evaluate the diagnostic and prognostic potential of cardio-enriched
miRNAs in patients presenting with a suspected acute coronary syndrome (ACS).
Methods: Cardio-enriched miRNAs (miR-1, miR-208b and miR-499-5p) were measured using real time PCR in
plasma samples from 424 patients with suspected ACS treated in a coronary care unit. miRNAs were assessed for
discrimination of a clinical diagnosis of myocardial infarction and for association with 30-day mortality and
diagnosis of heart failure. Correlation with left ventricular systolic dysfunction as measured by the ejection fraction
(LVEF) was also assessed. To confirm myocardial origin miRNA was measured during coronary artery bypass surgery.
Results: miRNAs were higher in MI patients and correlated with LVEF (p < 0.001). Discrimination of MI was accurate
for miR-208b (AUC = 0.82) and miR-499-5p (AUC = 0.79) but considerable lower than for Troponin T (AUC = 0.95).
Increased miRNA levels were strongly associated with increased risk of mortality or heart failure within 30 days for
miR-208b (OR 1.79, 95% CI = 1.38-2.23, p = 1 × 10-5) and miR-499-5p (OR 1.70, 95% CI = 1.31-2.20, p = 5 × 10-5) but
the association was lost when adjusting for Troponin T. During surgery miR-208b and miR-499-5p was released in
the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein.
Conclusions: Our findings confirm increased levels of cardio-enriched miRNAs in the blood of MI patients and establish
association of increased miRNA levels with reduced systolic function after MI and risk of death or heart failure.
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MicroRNA (miRNA) is a class of short non-coding
RNA, which function as moderators of gene expression
[1-3]. miRNA binds to complementary sequences in the
3’ untranslated region of mRNA and thereby facilitates
down regulation of gene expression. The expression of
miRNA is in itself subject to tight regulation, both tem-
porally and spatially [4], and some miRNA species are
highly tissue specific [5-7]. Cardio-enriched miRNAs
play a crucial role in cardiac development [8,9] and
have been associated with the development of dilated
cardiomyopathy [10]. In the event of tissue damage or* Correspondence: olof.gidlof@med.lu.se
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reproduction in any medium, provided the orstress, it is believed that cells release some of their
miRNA content into the circulation [11-14]. The fact
that most miRNA species are remarkably stable and
readily detectable in blood makes them excellent candi-
date biomarkers for various diseases, including myocar-
dial infarction and heart failure [15-18].
Biomarkers play a central role in the diagnosis and
prognostication in myocardial infarction, but current
biomarkers like creatine kinase MB (CKMB) and cardiac
troponins have several shortcomings, including slow re-
lease patterns [19] or limitations in specificity [20]. The
prospect of using circulating cardio-enriched miRNA as
biomarkers for myocardial infarction has been explored
in several studies [21-24]. However, most studies
conducted thus far have been small and focused on the
acute phase of the disease. We assessed the usefulness oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and -499-5p, previously shown to be elevated in plasma
following myocardial infarction, both for distinguishing
myocardial infarction (MI) from non-MI chest pain in
the acute phase and for long-term prognosis of death
and development of heart failure in a large population of
patients presenting with acute coronary syndrome
(ACS). Moreover, to confirm the myocardial origin of
these miRNAs, we analysed the miRNA content in the
coronary sinus before and immediately after cardioplegia
in patients undergoing coronary artery bypass surgery.
Methods
CABG patient samples
Four patients undergoing coronary artery bypass
grafting (CABG) were included in the study. Patient
characteristics are described in Table 1. Blood samples
were taken from the coronary sinus before and immedi-
ately after cardioplegia. As a control, blood was also
sampled from a peripheral artery immediately after
cardioplegia. Plasma was prepared by centrifugation at
1500*g for 15 minutes and stored at -80°C until analysis.
ACS patient samples
All patients presenting with suspected ACS pain in the
coronary care unit at Skane University Hospital in Lund
were offered to take part in the study. See Table 2 for
patient characteristics. ST-elevation myocardial infarc-
tion (STEMI) diagnosis was based on ECG criteria,
non-STEMI (NSTEMI) on troponin levels together
with clinical symptoms of ischemia. Non-MI was
defined as absence of troponin-elevation and absence of
ST-elevation. A peripheral venous blood sample was
drawn into tubes containing EDTA, plasma was
prepared as described above and stored in liquid nitro-
gen until analysis. 71% of blood samples were taken
within 24 hours, 82% within 48 hours and 93% within 72 -
hours. In 90% of the patients, samples were obtained
after interventional therapy. 95% of patients were treated
with percutaneous coronary intervention (PCI). Left ven-
tricular ejection fraction (LVEF) was assessed withTable 1 CABG Patient characteristics
Characteristic Patient 1 Patient 2 Patient 3 Patient 4
Age 61 84 65 80
Sex M M F M
Diabetes Mellitus Y N N N
Hypertonia Y N Y Y
Smoking C E E E
Preoperative MI Y N N Y
Aortic Valve Stenosis N Y Y N
M = Male, F = Female, Y = Yes, N = No, C = Current smoker, E = Ex-smoker.echocardiography before discharge. Troponin T was
measured using a standard clinical high sensitivy tropo-
nin method. Samples were taken at admission, at 3, 10
and 20 hours. Daily repeated samples were taken until a
peak value had been identified.
Sample preparation and laboratory analysis
Before analysis, plasma samples were thawed on ice and
250 μl aliquots were mixed 1:3 with TRIzol LS (Invitrogen,
Carlsbad, USA). Samples were vortexed for >30 seconds
and total RNA (including miRNA) was isolated using the
miRNeasy kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. cDNA was prepared using
miRCURY LNA Universal cDNA synthesis kit (Exiqon,
Vedbaek, Denmark) according to the manufacturer’s
instructions. Genomic DNA contamination was assessed
with no-reverse transcriptase controls. Quantitative real-
time polymerase chain reaction (qRT-PCR) was carried out
in 10 μl duplicate reactions, using Fast SYBR Green Master
Mix (Applied Biosystems, Carlsbad, USA) with LNA
primer sets (Exiqon) specific for the three human
cardio-enriched miRNAs miR-1 (gene symbol: MIR1,
miRBase accession number: MIMAT0000416) miR-208b
(MIR208A, MIMAT0004960) and miR-499-5p (MIR499A,
MIMAT0002870) as well as the control miRNA miR-17
(MIR17, MI0000071) and 4 μl of 80× diluted cDNA
preparation on a StepOnePlus Real-Time PCR System
(Applied Biosystems). Thermal cycling consisted of an
initial denaturation at 95°C for 20 s, followed by 40
cycles of 95°C for 3 s and 60°C for 30 s. A melt curve
was performed after each PCR. All PCR reactions
yielded a single peak on the melt curve, indicating ac-
ceptable specificity of the primers. No template controls
were added on each plate and in case of amplification
in these wells the plate was rerun. Calibration curves
were run to validate each assay. For miR-1 slope = -3.42,
y-intercept = 40.23, r2 = 0.99, efficiency = 96%, linear
range = 6.55*105 - 40 copies, limit of detection (LOD) = 40
copies, Ct standard deviation at LOD= 0.15, intraassay vari-
ation = 0.03, for miR-208b, slope = -3.38, y-intercept = 38.57,
r2 = 0.98, efficiency = 97.7%, linear range = 2.6*106-10 copies,
LOD =10 copies, Ct standard deviation at LOD= 0.59,
intraassay variation = 0.05, for miR-499-5p slope = -3.37,
y-intercept = 39.43, r2 = 0.97, efficiency = 98%, linear
range = 2.6*106-160 copies, LOD =160 copies, Ct stan-
dard deviation at LOD= 0.11, intraassay variation = 0.04.
When preparing RNA from plasma, the yields are in-
sufficient for proper quantitation with e.g. NanoDrop
[21]. Therefore, equal volumes of RNA preparation, ra-
ther than equal RNA amounts, was used as input in
the cDNA synthesis. Normalization for variations in
RNA input was conducted using miR-17, which is
stable and abundant in plasma and is unaffected by
myocardial damage [21]. In our samples, miR-17 varied
Table 2 ACS Patient characteristics
Characteristic Distribution total cohort Distribution experienced endpoint Distribution no end-point p
Sample size 407 74 333
Age 65 (11.1) 67.8 (11.8) 64.5 (10.9) 0.02
Men 76.9% 78.1% 76.6% 0.79
Diabetes Mellitus 17.2% 17.8% 17.1% 0.88
Hypertonia 43.5% 52.1% 41.6% 0.10
Current Smoking 24.8% 23.3% 25.1% 0.74
Mean time to sample (hours) 38.4 (32.2) 42.7 (13.7) 38.2 (6.9) 0.28
Diagnosis 0.04
STEMI 42.5% 53.4% 40.1% 0.79
NSTEMI 35.9% 35.6% 35.9%
Non-MI 21.6% 11.0% 24.0%
Unstable angina 63,6% 85.7% 62,5%
Stable angina 21,6% 0% 26.2%
Chest pain 14,8% 14.3% 11.2%
Troponin T (ng/l) 2.55 (3.76) 5.14 (5.25) 1.98 (3.08) <0.0000001
Concurrent therapy
Aspirin 35.1% 34.2% 35.3% 0.79
Beta-adrenergic antagonists 32.4% 56.2% 29.9% 0.05
Ca2+-channel antagonists 17.7% 19.2% 17.4% 0.61
Statins 31.7% 35.6% 30.8% 0.60
ACE inhibitors 17.7% 26.0% 15.9% 0.08
Death within 3 months (%) 1.2% 6.8% 0% 0.000001
LVEF <0.0000001
>50% 62.8% 5.6% 78.7%
40-49% 17.4% 5.6% 21.3%
30-39% 14.5% 67.6% 0%
<30% 4.4% 21.1% 0%
miRNA (ln 2-ΔCt)
miR-1 −2.69 (0.99) −2.58 (1.08) −2.71 (0.97) 0.32
miR-208b −4.59 (2.22) −3.70 (2.38) −4.78 (2.14) 0.0001
miR-499-5p −4.77 (1.80) −4.03 (2.04) −4.93 (1.71) 0.00009
Continuous variables are presented as sample mean and standard deviation. P-values reflect comparisons between “Experienced endpoint” and “No endpoint”
and are derived from Student’s t-tests for continuous variables and from Pearson’s chi-squared tests for frequency distributions. P-values below the threshold for
statistical significance are bolded. STEMI, ST-elevation myocardial infarction; NSTEMI, non ST-elevation myocardial infarction; MI, myocardial infarction; LVEF, left
ventricular ejection fraction.
Gidlöf et al. BMC Cardiovascular Disorders 2013, 13:12 Page 3 of 9
http://www.biomedcentral.com/1471-2261/13/12little between patients, with a coefficient of variation
of 5.7%. To confirm that miR-17 was stable across pa-
tient groups a one-way ANOVA was conducted on
raw Ct values and the means did not differ significantly
between groups (p = 0.698). Samples where miR-17 was
not detected were regarded as poor quality RNA and
those patients were excluded from the analysis (n = 10).
The threshold cycle (Ct) was defined manually for each
plate and was set where all assays were in the log linear
phase and the threshold was above background for all
assays. Ct-values > 37 were considered as unspecific
amplification. All samples where miR-1, miR-208b ormiR-499-5p was not detected were given the Ct-value 37
(1% of patients for miR-1, 33% for miR-208b and 24%
for miR-499-5p). To adjust for differences in the amount
of total RNA in each sample, Ct-values were normalized
against miR-17 (ΔCt) and transformed into quantities
using the formula 2-ΔCt. An inter-plate calibrator sample
was used to normalize for run-to-run variation.
Statistical analysis
Plasma miRNA quantity was transformed using the nat-
ural logarithm as the distribution was positively skewed
upon visual inspection. Patients whose blood samples
Figure 1 Circulating miRNA levels in CABG patients. MiRNA levels
relative to miR-17, transformed into quantities using the formula 2-dCt.
Error bars represent standard error of the mean (SEM). N.D. = not
detectable, C.S. = coronary sinus, P.A. = peripheral artery. **p < 0.01.
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patients whose admission date had not been registered
(n = 2) were excluded from the analysis.
First, the distribution of each miRNA was compared
across patient groups (STEMI, NSTEMI, non-MI)
using one-way analysis of variance (ANOVA). Second,
we determined the ability of miRNA level to discrim-
inate between MI and non-MI patients, using Re-
ceiver Operator Characteristic (ROC) analysis. Third,
we examined the long-term prognostic impact of
elevated miRNA levels. The primary endpoint was
predefined as death within 30 days of hospitalization
(n = 5) or development of heart failure (clinical diag-
nosis (n = 25), an ejection fraction < 40% (n = 65) or
development of cardiogenic shock (n = 2)) during
follow-up. ROC analysis was then used to assess and
compare the prognostic value of miRNAs and Tropo-
nin T using the primary endpoint as state variable.
Finally, correlation of miRNA levels and LVEF and
Troponin T (TnT) was tested using Spearman’s rank
correlation coefficient. All statistical analyses were
performed in SPSS Statistics v.19.0.0 (IBM, Armonk,
USA).
Ethics
All patients gave their informed consent before being
included in the study. The study was approved by the
local ethics committee of Skane University Hospital
and carried out in compliance with the Declaration of
Helsinki.
Results
Circulating miR-208b and miR-499-5p specifically reflect
myocardial damage
To confirm that miR-208b and miR-499-5p are
released directly from the myocardium as a result of
tissue damage, we analysed miRNA levels in the co-
ronary sinus of CABG-patients before and immediately
after cardioplegia (see Figure 1). miR-208b and miR-
499-5p were undetectable in the coronary sinus
before cardioplegia but became readily detectable im-
mediately after. The levels of miR-208b were signifi-
cantly higher in the coronary sinus than in the
periphery after cardioplegia (p < 0.01). For miR-499
-5p, levels were higher in the coronary sinus than in
the periphery but the difference did not reach statis-
tical significance.
Levels of circulating miRNA in ACS patients
A total of 424 patients with suspected ACS were
included and underwent measurement of plasma levels
of miR-1, -208b, and -499-5p. Of these, 17 samples were
excluded due to poor RNA quality (n = 10), excessive
time from admission to sampling (>1 week, n = 5) orfailure to register admission date (n = 2). A majority
(76.2%) of patients were men and the median age was
65 years. 173 patients were diagnosed with STEMI,
146 with NSTEMI and 88 as non-MI. In the non-MI
group, 64% were diagnosed with unstable angina,
22% with stable angina and 14% were defined as
general chest pain. Patient characteristics are
summarized in Table 2. Distributions of each miRNA
across patient groups are shown in Figure 2. The
levels of miR-208b and miR-499-5p were significantly
Figure 2 MiRNA levels across patient groups. MiRNA levels
relative to miR-17, transformed into linear form using the formula 2-dCt.
All quantities have been transformed using the natural logarithm. The
box extends from the 25th percentile to the 75th percentile with a line
at the median. The whiskers indicate the highest and the lowest value
in each group. *p < 0.05, ***p < 0.001.
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compared to non-MI patients (p < 0.001). miR-208b
and -499-5p were also significantly higher in STEMI
than in NSTEMI patients (p < 0.001). The levels of
miR-1 were slightly higher in NSTEMI patients
compared to the non-MI group (p < 0.05).
Diagnosis of myocardial infarction
ROC curves describing the discrimination of patients
diagnosed with MI (n = 319) from non-MI patients
(n = 88) with circulating miRNA levels as well as the
levels of the current cardiac marker Troponin T are
shown in Figure 3.
The best discriminatory characteristics for a miRNA
were observed for miR-208b, with an area under the
ROC curve (AUC) of 0.82. miR-499-5p had an AUC of
0.79 whereas the AUC for miR-1 was 0.57. The current
cardiac marker Troponin T (TnT) had an AUC of 0.95.
Prognosis after myocardial infarction
A total of 74 patients (18%) experienced the primary
endpoint. Plasma levels of miR-208b and miR-499-5p
were associated with the primary endpoint. Odds ratios,
adjusted for age, sex, time from admission to sampling
and calculated per quartile, were 1.79 (95% CI = 1.38-2.33,
p = 1 × 10-5) for miR-208b and 1.70 (95% CI = 1.31-2.20,
p = 5 × 10-5) for miR-499-5p. When adjusting also for
TnT, statistical significance was lost (p = 0.21 for miR-
208b and 0.11 for miR-499-5p, respectively). Figure 4a
depicts the proportion of patients in each quartile that
experienced the primary endpoint. The relative miRNA
levels in each quartile are shown in Figure 4b. In
patients with MI (n = 319), miR-208b and miR-499-5p
were still significantly associated with the primary
endpoint (OR = 1.71, 95% CI = 1.25-2.34, p = 0.001 for
miR-208b and OR = 1.58, 95% CI = 1.17-2.13, p = 0.003
for miR-499-5p, respectively) while there were no signifi-
cant associations in the non-MI group (OR = 1.55, 95%
CI = 0.55-4.40, p = 0.41 for miR-208b and OR = 1.64, 95%
CI = 0.60-4.51, p = 0.33 for miR-499-5p, n = 88). In
patients aged 75 or older (n = 89), the risk of experiencing
the primary endpoint was higher than in younger patients.
For miR-208b, OR = 2.20 (95% CI 1.26-3.82, p = 0.005) in
patients >75 years old compared to 1.66 (95% CI 1.21-2.26,
p = 0.001) for patients <75 years old. For miR-499-5p,
the respective odds ratios were 1.99 (95% CI 1.20-3.32,
p = 0.008) and 1.59 (95% CI = 1.17-2.16, p = 0.003), re-
spectively. miR-1 levels were not significantly associated
with the primary endpoint in any of the analyses.
To further assess the prognostic value of miR-208b
and miR-499-5p compared to TnT, ROC analysis was
performed with the primary endpoint as the state vari-
able (Figure 5). Both miRNAs had similar accuracy as
TnT (AUC = 0.64 for both miRNAs and 0.66 for TnT).
Figure 3 Discrimination of myocardial infarction. ROC curves
describing the discrimination of patients diagnosed with MI from
non-MI patients with circulating miRNA levels as well as Troponin T.
Figure 5 Prognostic accuracy of miRNAs and Troponin T. ROC
curves for miR-208b, miR-499-5p and Troponin T with the primary
endpoint as state variable.
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In order to further evaluate the usefulness of circulating
miRNA as cardiac biomarkers, we tested whether the
levels of miR-1, -208b and -499-5p correlated with TnT.
miR-208b and -499-5p were strongly correlated withFigure 4 Association of miRNA with the primary endpoint. a) The leve
proportion of patients (%) in each quartile who experienced the primary
miR-17 and transformed into linear form using the formula 2-dCt.TnT (r = 0.65, p < 1*10-7 and r = 0.62, p < 1*10-7) as well
as with one another (r = 0.93, p < 0.0000001). Adjusting
for age, sex and time from admission to sampling did
not affect the level of statistical significance. miR-1 was
weakly correlated with TnT (r = 0.12, p = 0.02), but lostl of each miRNA was divided into quartiles. Each bar represents the
endpoint. b) Levels of miRNA in each quartile, expressed relative to
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sampling time. In subgroup analyses, TnT remained
correlated with miRNA levels in MI patients (r = 0.57,
p < 1*10-7 for miR-208b and r = 0.55, p < 1*10-7 for miR-
499-5p) but not in non-MI patients (r = 0.1, p = 0.37 for
miR-208b and r = 0.2, p = 0.08 for miR-499-5p).
We also investigated whether an increase in circulating
cardio-enriched miRNA correlated with long-term myo-
cardial systolic function, as measured by a LVEF. All
miRNAs were weakly negatively correlated with LVEF
(r = -0.11, p = 0.037 for miR-1; r = -0.16, p = 0.003 for
miR-208b; r = -0.16, p = 0.003 for miR-499-5p). In sub-
group analyses, LVEF was negatively correlated with
miRNA in MI patients but not in non-MI patients. In
multivariate analysis, the level of statistical significance
for all correlations were unaffected by adjustment for
age, sex and sampling time. Scatter plots for all correlations
are shown in Additional file 1: Figure S1 and S2.
Discussion
The notion of circulating miRNA as biomarkers for vari-
ous diseases has been explored to a considerable extent
in recent years. Tissue specificity, rapid release dynamics
and stability in blood [21-24] and urine [23] make
miRNAs promising candidates for diagnostic and prog-
nostic utility in a wide range of disease states. miRNA
species expressed at particularly high levels in cardiac or
skeletal muscle, such as miR-1, miR-133, miR-208a/b
and miR-499-5p have been thought of as candidate
biomarkers in ACS. Thus far, most studies related to
these questions have been small and focused on the
acute phase of the disease. We wanted to investigate
whether circulating cardio-enriched miRNA are valuable
both for diagnosis and prognosis in a larger cohort of
patients with suspected ACS.
Although many studies have claimed that the presence
of cardio-enriched miRNA in the circulation reflect
myocardial damage[15,16,21,22], only one very recent
study have tried to show direct evidence that these
miRNA species are in fact released directly from human
myocardium [25]. To address this, we sampled blood
from the coronary sinus before and after cardioplegia
and reperfusion in patients undergoing CABG. The
presence of miR-208b and miR-499-5p in the coronary
sinus immediately after, but not before cardioplegia,
supports the idea that these miRNAs are in fact released
directly from the myocardium following tissue damage.
Although the conditions during CABG do not directly
reflect the situation in MI, these are both states of cir-
culatory standstill within the myocardium and a
reperfusion injury that amounts to tissue stress and
cell death. Our data provides indirect evidence that
miR-208b and miR-499-5p are released specifically
from the heart in man.The levels of all three cardio-enriched miRNAs
displayed the same pattern, with increased amounts in
NSTEMI patients compared to non-MI and increased
amounts in STEMI patients compared to NSTEMI. This
partly contradicts the results of a recent study [26],
where the level of miR-499 was not increased in STEMI/
NSTEMI compared to non-MI. However, this is not
entirely unexpected since the release pattern of miR-
499-5p is slower than that of miR-1/-208b [23] and
the samples were taken at a later time point in this
study compared to the study by Widera et al. It is
possible that the peak of miR-499-5p had not yet been
reached at the time of sampling in that study.
Although MI patients could be discriminated from non-
MI patients based on the plasma levels of miR-208b and
miR-499-5p, the accuracy was well below that of the
current gold standard cardiac marker, Troponin T. How-
ever, it is likely that the accuracy could be improved with
faster blood sampling, considering the rapid dynamics of
circulating cardio-enriched miRNAs [21] and the fact that
29% of the blood samples were taken more than 24 hours
after admission. In fact, a subgroup analysis with only the
samples that were taken within 24 hours showed a mark-
edly improved diagnostic accuracy. AUC for miR-208b
increased from 0.82 to 0.89 and from 0.79 to 0.87 for miR-
499-5p. Another factor that hampers a direct comparison
is that blood sampling for miRNA and TnT analysis was
not consistently obtained at the same time point.
To evaluate whether circulating miRNA holds any prog-
nostic value we evaluated a primary endpoint including
death within thirty days of admission and development of
heart failure. Plasma levels of miR-208b and miR-499-5p
were associated with an increased risk of death or heart
failure in MI patients (STEMI and NSTEMI) but not in
non-MI patients and may thus provide some prognostic in-
formation following MI. An increased level of either of the
three miRNAs also correlated with decreased systolic func-
tion, confirming the findings of our recent, smaller study
[23]. It is likely that the release of cardio-enriched miRNAs
into the bloodstream following myocardial damage is
merely a by-product of necrotic cardiomyocytes. However,
the possibility of a paracrine effect of these miRNA species,
as e.g. shown for miR-126 in the context of atherosclerosis
[13], which might exacerbate the conditions within the
myocardium post-MI and increase the risk of death or de-
velopment of heart failure, cannot be excluded.
During preparation of this manuscript one other large
study evaluating the prognostic impact of cardio-
enriched miRNAs on survival in the context of ACS was
published [26]. miR-133 and -208b was associated with
an increased risk of death within six months. As with
the results presented herein, the association did not re-
main statistically significant after adjusting for another
cardiac biomarker. These findings suggest that miRNA
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regarding risk of death or development of heart failure
than the current cardiac markers. However, the most im-
portant potential utility of these new biomarkers lie in
the rapid release dynamics and substantial rise in plasma
levels. Additional studies are warranted to assess the
utility of miRNAs in rapid diagnosis of MI in the emer-
gency department and in the diagnosis of early
reinfarction, where conventional biomarkers perform
poorly. Additional studies are also warranted in patient
groups where traditional cardiac markers are less reli-
able, for example in the elderly, and in patients with se-
vere heart failure or renal failure and dialysis.
Our study also has limitations which merit consider-
ation. First, the CABG patient cohort consists of only
four individuals and the results regarding the origin of
cardio-enriched miRNAs must be taken with caution.
Second, as patients were recruited at the coronary care
unit, our study did not include many patients presenting
with possible ACS of lower likelihood to represent ische-
mic heart disease, which are more often treated in a gen-
eral acute admissions unit. This may have attenuated the
diagnostic performance of biomarkers, as patients trans-
ferred to the coronary care unit more often have concur-
rent cardiac disease or other complicating factors, which
may be associated with increased biomarker levels.
Third, comparisons of miRNA and Troponin T are
complicated by the fact that these samples were not con-
sistently obtained at the same time point.
Conclusion
In conclusion, our findings indicate that cardio-enriched
miRNAs are released from the myocardium in response to
ischemia, that the levels of cardio-enriched miRNAs are
increased in MI and establish association of increased
miRNA levels with reduced systolic function after MI and
risk of death or heart failure.
Additional file
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